Knobbe Martens Client OptiScan Biomedical’s OptiScanner® 5000 Receives 510(k) Clearance from US Food and Drug Administration for the First Inline Continuous Glucose Monitor in the SICU
The OptiScanner® 5000 is an automated, bedside glucose monitoring system that provides physicians with information on plasma glucose levels in the SICU. Through automated monitoring of a patient’s glucose values, the OptiScanner has alarms to alert clinicians to the existence of hyperglycemia (values that are too high) and hypoglycemia (values that are too low).
It is estimated that approximately 20 percent of ICU patients have pre-existing diabetes and an additional 40 to 60 percent of ICU patients suffer from “stress hyperglycemia” or a temporary elevation of glucose levels, with all of these patients requiring accurate glucose monitoring to maintain glycemic control. Read more on the OptiScan Biomedical website.
Partners Bill Bunker and Philip Nelson manage OptiScan’s patent portfolio.
About Knobbe Martens
Consistently ranked among the top intellectual property firms in the nation and worldwide, Knobbe Martens has over 275 lawyers and scientists nationwide and dedicates its practice to all aspects of intellectual property and technology law, including litigation. Knobbe Martens serves a diverse group of clients from multinational corporations to emerging businesses of all stages. The firm is headquartered in Orange County, California, with offices in Los Angeles, New York, San Diego, San Francisco, Seattle, Silicon Valley and Washington, D.C., and enjoys an international reputation for excellence. More information about the firm can be found at http://www.knobbe.com.
